KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Assets Average (2016 - 2025)

Sarepta Therapeutics has reported Assets Average over the past 15 years, most recently at $3.4 billion for Q4 2025.

  • For Q4 2025, Assets Average fell 9.52% year-over-year to $3.4 billion; the TTM value through Dec 2025 reached $3.4 billion, down 9.52%, while the annual FY2025 figure was $3.7 billion, 1.18% up from the prior year.
  • Assets Average for Q4 2025 was $3.4 billion at Sarepta Therapeutics, down from $3.6 billion in the prior quarter.
  • Over five years, Assets Average peaked at $3.8 billion in Q4 2024 and troughed at $2.7 billion in Q3 2021.
  • A 5-year average of $3.2 billion and a median of $3.1 billion in 2022 define the central range for Assets Average.
  • Biggest five-year swings in Assets Average: rose 20.54% in 2021 and later dropped 9.52% in 2025.
  • Year by year, Assets Average stood at $2.9 billion in 2021, then rose by 8.16% to $3.1 billion in 2022, then increased by 1.43% to $3.2 billion in 2023, then increased by 18.65% to $3.8 billion in 2024, then dropped by 9.52% to $3.4 billion in 2025.
  • Business Quant data shows Assets Average for SRPT at $3.4 billion in Q4 2025, $3.6 billion in Q3 2025, and $3.6 billion in Q2 2025.